Merrill keeps Alexion at buy

Merrill Lynch analyst David Munno kept Alexion Pharmaceuticals Inc. at its buy rating on news that the Food and Drug Administration granted priority review to Alexion's Soliris, setting a March 20 PDUFA date. The analyst expects Soliris to be approved in the United States and the European Union in the first half of 2007. Shares of the Cheshire, Conn.-based biotechnology company were down 95 cents, or 2.22%, at $41.82. (Nasdaq: ALXN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.